Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Insights into the role of IL-32 in cancer.

Sloot YJE, Smit JW, Joosten LAB, Netea-Maier RT.

Semin Immunol. 2018 Aug;38:24-32. doi: 10.1016/j.smim.2018.03.004. Epub 2018 May 8. Review.

PMID:
29747940
2.

Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Park JS, Choi SY, Lee JH, Lee M, Nam ES, Jeong AL, Lee S, Han S, Lee MS, Lim JS, Yoon DY, Kwon Y, Yang Y.

Cell Oncol (Dordr). 2013 Dec;36(6):493-503. doi: 10.1007/s13402-013-0154-4. Epub 2013 Oct 10.

PMID:
24114327
3.

Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines.

Heinhuis B, Plantinga TS, Semango G, Küsters B, Netea MG, Dinarello CA, Smit JWA, Netea-Maier RT, Joosten LAB.

Carcinogenesis. 2016 Feb;37(2):197-205. doi: 10.1093/carcin/bgv172. Epub 2015 Dec 17.

PMID:
26678222
4.

Interleukin 32, inflammation and cancer.

Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH.

Pharmacol Ther. 2017 Jun;174:127-137. doi: 10.1016/j.pharmthera.2017.02.025. Epub 2017 Feb 14. Review.

PMID:
28223235
5.

Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis.

Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LA.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4962-7. doi: 10.1073/pnas.1016005108. Epub 2011 Mar 7.

6.

Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA.

Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, Yu DY, Song EY, Lee HG, Sohn JH, Kim J, Dinarello CA, Yoon DY.

J Immunol Methods. 2008 Apr 20;333(1-2):38-50. doi: 10.1016/j.jim.2007.12.017. Epub 2008 Jan 28.

PMID:
18252253
7.

The role of the IL-22/IL-22R1 axis in cancer.

Lim C, Savan R.

Cytokine Growth Factor Rev. 2014 Jun;25(3):257-71. doi: 10.1016/j.cytogfr.2014.04.005. Epub 2014 May 9. Review.

PMID:
24856143
8.

A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10.

Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY, Yoon DY.

Immunology. 2009 Sep;128(1 Suppl):e532-40. doi: 10.1111/j.1365-2567.2008.03025.x. Epub 2008 Dec 18.

9.

Novel insights into the biology of interleukin-32.

Joosten LA, Heinhuis B, Netea MG, Dinarello CA.

Cell Mol Life Sci. 2013 Oct;70(20):3883-92. doi: 10.1007/s00018-013-1301-9. Epub 2013 Mar 6. Review.

PMID:
23463238
10.

Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis.

Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH, Lin KH.

Clin Cancer Res. 2014 May 1;20(9):2276-88. doi: 10.1158/1078-0432.CCR-13-1221. Epub 2014 Mar 6.

11.

Targeting interleukin-22 for cancer therapy.

Markota A, Endres S, Kobold S.

Hum Vaccin Immunother. 2018;14(8):2012-2015. doi: 10.1080/21645515.2018.1461300. Epub 2018 May 17.

12.

Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells.

Schmieder A, Multhoff G, Radons J.

Cytokine. 2012 Nov;60(2):514-21. doi: 10.1016/j.cyto.2012.06.286. Epub 2012 Jul 20.

PMID:
22819319
13.

Interleukin-32: An endogenous danger signal or master regulator of intracellular pathogen infections-Focus on leishmaniases.

Dos Santos JC, Damen MSMA, Joosten LAB, Ribeiro-Dias F.

Semin Immunol. 2018 Aug;38:15-23. doi: 10.1016/j.smim.2018.02.010. Epub 2018 Mar 15. Review.

PMID:
29551246
14.

Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma.

Semango G, Heinhuis B, Plantinga TS, Blokx WAM, Kibiki G, Sonda T, Mavura D, Masenga EJ, Nyindo M, van der Ven AJAM, Joosten LAB.

Am J Pathol. 2018 Jan;188(1):196-203. doi: 10.1016/j.ajpath.2017.08.033. Epub 2017 Oct 14.

PMID:
29037857
15.

IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals.

Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, Ban JO, Kang JW, Lee DH, Shim JH, Han SB, Moon DC, Park YH, Yu DY, Kim JM, Kim SH, Yoon DY, Hong JT.

Oncogene. 2011 Jul 28;30(30):3345-59. doi: 10.1038/onc.2011.52. Epub 2011 Mar 21.

16.

IL-35 induces N2 phenotype of neutrophils to promote tumor growth.

Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, Luo C, Wang SS, Chi G, Guo F, Zhang GM, Feng ZH.

Oncotarget. 2017 May 16;8(20):33501-33514. doi: 10.18632/oncotarget.16819.

17.

Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA.

J Biol Chem. 2012 Feb 17;287(8):5733-43. doi: 10.1074/jbc.M111.288290. Epub 2011 Dec 27.

18.

Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA.

Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S, Jhun H, Hong K, Kim E, Jo S, Her E, Kim S.

Hybridoma (Larchmt). 2010 Dec;29(6):501-9. doi: 10.1089/hyb.2010.0059. Epub 2010 Nov 18.

PMID:
21087097
19.

IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection.

Li W, Sun W, Liu L, Yang F, Li Y, Chen Y, Fang J, Zhang W, Wu J, Zhu Y.

J Immunol. 2010 Nov 1;185(9):5056-65. doi: 10.4049/jimmunol.0902667. Epub 2010 Oct 1.

20.

Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19.

Fietta P, Costa E, Delsante G.

Theor Biol Forum. 2014;107(1-2):13-45. Review.

PMID:
25936211

Supplemental Content

Support Center